Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03769194 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 572
- Enrollment target
NCT03769194 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 572 participants.
The verdict
NCT03769194, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 572 participants
- Enrollment target
Study Summary
This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study conducted in two study phases: a run-in phase and a main study phase. The study was investigated 3 doses of a multivalent OspA (Outer Surface Protein A) based Lyme vaccine (VLA15) in healthy adults aged 18 to 65 years of age. Study participants received 3 immunizations of the vaccine at a monthly interval. The study assessed the immune response as well as the safety profile of the vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLA15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2018-12-17 |
| Est. Completion | 2020-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03769194
The ClinicalTrials.gov registry entry for NCT03769194 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03769194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03769194 about?
NCT03769194 is a clinical study titled "Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.". This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study conducted in two study phases: a run-in phase and a main study phase. The study was investigated 3 doses of a multivalent OspA (Outer Surface Protein A) based Lyme vaccine (VLA15) in healthy adults aged 18 to 65 year...
What is the current status of trial NCT03769194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 572 participants. The study started on 2018-12-17. Estimated completion is 2020-10-02.
What interventions are being tested in trial NCT03769194?
The interventions under investigation include: Placebo (BIOLOGICAL), VLA15 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03769194?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.